Skip to main content
Erschienen in: Respiratory Research 1/2017

Open Access 01.12.2017 | Review

WNT signaling – lung cancer is no exception

verfasst von: Judit Rapp, Luca Jaromi, Krisztian Kvell, Gyorgy Miskei, Judit E. Pongracz

Erschienen in: Respiratory Research | Ausgabe 1/2017

Abstract

Since the initial discovery of the oncogenic activity of WNT ligands our understanding of the complex roles for WNT signaling pathways in lung cancers has increased substantially. In the current review, the various effects of activation and inhibition of the WNT signaling pathways are summarized in the context of lung carcinogenesis. Recent evidence regarding WNT ligand transport mechanisms, the role of WNT signaling in lung cancer angiogenesis and drug transporter regulation and the importance of microRNA and posttranscriptional regulation of WNT signaling are also reviewed.
Abkürzungen
ABC
ATP-binding cassette
ABCB1
ATP-binding cassette transporter protein B1
ABCG2
ATP-binding cassette transporter protein G2
AC
adenocarcinoma
AE
alveolar epithelium
AEC
alveolar epithelial cell
ALK
anaplastic limphoma kinase
AP
activator protein
APC
adenomatous polyposis coli
AT
alveolar type
AXIN
Axis inhibition protein
CaMKII
calcium calmodulin mediated kinase
CBP
CREB-binding protein
CDX
caudal type homeobox
CHI3L3
chitinase-3 like 3
CREB
cAMP response element-binding protein
CSC
cancer stem cell
DAAM
disheveled associated activator of morphogenesis
DACT
Dapper homolog
DKK
Dickkopf-related protein
DNMT3A/3B
DNA methyltransferase 3 alpha/ 3 beta
DVL
Disheveled
E-cadherin
epithelial cadherin
EGFR
epidermal growth factor receptor
EMT
epithelial-mesenchymal transformation
EMX
empty spiracles homeobox
EpCAM
epithelial cell adhesion molecule
FGF
fibroblast growth factor
FLOT
flotillin
FRP
Frizzled-related protein
FZD
Frizzled receptor
GPC
glypican
GSK-3-beta
glycogen synthase kinase 3-beta
HDPR
human homolog of Dapper
HIF1alpha
hypoxia-inducible factor 1 alpha
HNF4A
hepatocyte nuclear factor 4 alpha
IGF
insulin-like growth factor
ING
inhibitor of growth family
JNK
Jun N-terminal kinase
LC
lung cancer
LCC
large cell carcinoma
LEF
lymphoid enhancer-binding factor
LGR
leucin-rich repeat containing G-protein coupled receptor
LRP
lipoprotein receptor-related protein
miRNA
microRNA
MMP
matrix metalloproteinase
N-cadherin
neural cadherin
NFAT
nuclear factor of activated T-cell
NKD
naked cuticle homolog
NLK
nemo-like kinase
NSCLC
non-small cell lung cancer
OCT
octamer-binding transcription factor
PCP
planar cell polarity
PE
primordial epithelium
PKC
protein kinase C
PNEC
pulmonary neuroendocrine cell
PPAR
peroxisome proliferator activated receptor
RAC1
Ras-related C3 botulinum toxin substrate 1
RAGE
receptor for advanced glycation end-product
Rb
retinoblastoma protein
RhoA
Ras homologue gene family member A
ROCK
Rhos-associated coiled-coil-containing protein kinase 1
ROR2
receptor tyrosine kinase-like orphan receptor
RUNX
runt-related transcription factor
RXR
retionid X receptor
RYK
receptor-like tyrosine kinase
SCC
squamous cell carcinoma
SCLC
small cell lung cancer
SHH
sonic hedgehog
SLC
solute carrier transporter
STAT
signal transducer and activator of transcription
TAK
transforming growth factor beta-activated kinase
TCF
T-cell factor
TGFbeta
transforming growth factor beta
TMEM
transmembrane protein
VE-cadherin
vascular endothelial cadherin
VEGF-A
vascular endothelial growth factor A
VEGFR
vascular endothelial growth factor receptor
WIF
WNT inhibitory factor
WNT
wingless/int

Background

Lung cancer (LC) is one of the deadliest forms of cancer worldwide [1, 2] affecting both genders [3, 4]. The two main types of LC-s are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC represents 15–20% of all LC cases and is the more aggressive form; it metastasizes early and therefore surgical intervention is rarely a therapeutic option [5]. On the other hand, NSCLC denotes 80–85% and can be further classified into adeno (AC)-, squamous cell (SCC) -, large cell (LCC) and various mixed type carcinomas [6]. Unfortunately, the majority of NSCLC patients are diagnosed at an advanced stage of the disease narrowing down therapeutic options and leading to a limited median survival of about 18 months [7]. Recent studies have confirmed that therapy-surviving cancer stem cells (CSC) play a cardinal role in drug resistance and therefore, rapid progression of the disease [8]. While the carcinogenic process in the lung can be traced back to genetic mutations, malfunctioning signaling pathways are also highly important modulators of tumor formation and individual features of the disease.
An increasing amount of evidence has shown that the WNT pathway is one of the main signaling pathways involved in maintaining lung homeostasis and that aberrant activation of this pathway may underlie several debilitating lung diseases. Similarly, to other human cancers, WNT signaling plays an important part in lung carcinogenesis. Interestingly, however, while some epigenetic changes that affect WNT pathway inhibitors are similar to those seen in other malignancies, genetic mutations of the WNT pathway are uncommon in NSCLCs [9].
This review will summarize some novel aspects of WNT signaling, what is currently known about WNT associated LC pathogenesis as well as some important features of WNT mediated events in LC therapies.

The complexity of WNT signaling – Canonical and non-canonical WNT signaling pathways

WNT proteins are secreted glyco-lipoprotein morphogens that are required during lung development for cell-fate specification, cell proliferation and the control of asymmetric cell division. In adults, WNT signaling is essential for stem cell maintenance for regulation of tissue homeostasis [10]. Most of the 19 WNT ligands and the 10 main receptors, Frizzleds (FZD) that have been identified in mammalian cells can be identified in the human lung [9, 11]. The two main different WNT pathways include i) the beta-catenin-dependent or canonical pathway, and ii) the beta-catenin-independent or non-canonical pathways including the planar cell polarity (PCP) and the WNT/Ca2+ pathways (Fig. 1).

Canonical or beta-catenin dependent WNT signaling.

In the lung, the role of WNT signaling has been examined in detail by multiple studies which mostly focus on beta-catenin-dependent signaling. In the canonical pathway during the absence of WNT, a beta-catenin destruction complex is assembled, consisting of: Axis inhibition protein (AXIN), adenomatous polyposis coli (APC), and glycogen synthase kinase 3-beta (GSK-3-beta) whereby beta-catenin is phosphorylated at serine and threonine sites and then proteolytically degraded [9, 12]. If WNT is available to bind to one of the ten FZD receptors then a receptor complex between WNT, FZD, lipoprotein receptor–related protein (LRP), Disheveled (DVL), and AXIN is formed [9]. Within this active complex, DVL becomes phosphorylated and eventually inhibits GSK-3-beta resulting in reduced phosphorylation and consequently stops the proteolytic destruction of beta-catenin. Beta-catenin subsequently accumulates in the cytoplasm. The cytoplasmic beta-catenin can then migrate to the nucleus and forms a complex with members of the T-cell factor (TCF)/Lymphoid enhancer-binding factor (LEF) family of transcription factors and transcriptional coactivators including cAMP response element-binding protein (CREB)–binding protein (CBP) and p300. The many target genes include c-myc and cyclin D1 [9]. The transmembrane receptor tyrosine kinase orphan receptor ROR2 (which is important in non-canonical WNT signaling) may also be involved in canonical signaling via interactions with FZD2 [13]. ROR2 [14], as well as the other WNT-binding receptors such as receptor-like tyrosine kinase RYK [15], can therefore act as regulatory receptors for the beta-catenin dependent WNT signaling.

Non-canonical WNT signaling

The two non-canonical WNT pathways are activated by several WNT ligands including WNT4, WNT5a, WNT7a, WNT11 and WNT16 [1618]. Activation of the PCP signaling pathway, for example by WNT11, leads to the activation of the small GTPases RhoA (RAS homologue gene-family member A) and RAC1 (Ras-related C3 botulinum toxin substrate 1). This, in turn, activates the stress kinases JNK (Jun N-terminal kinase) and ROCK (Rho-associated coiled-coil-containing protein kinase 1) that initiates remodeling of the cytoskeleton thus leading to changes in cell adhesion and motility [1921].
The best known activator of Ca2 + −dependent WNT signaling is WNT5a. It triggers signal transduction via DVL-3, heterotrimeric G proteins and phospholipases [22]. Activation of this pathway leads to a transient increase in cytoplasmic free Ca2+ level that in turn can activate the protein kinase C (PKC) family, CaMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin [23]. Apart from the well-known Ca2 + −dependent WNT signaling pathway, a novel, FYN tyrosine kinase and Signal Transducer and Activator of Transcription (STAT3) transcriptional regulator-mediated non-canonical WNT signaling pathway has also been identified in tumor cells [24].
Although WNT signaling pathways seem distinct, WNT proteins are promiscuous and can share receptors and regulate the expression of WNT signaling molecules, as well as modify WNT signaling pathway activity. Non-canonical WNT signaling, for example, represses canonical WNT activity via various mechanisms involving PKC-alpha, CaMKII-Transforming growth factor beta-Activated Kinase (TAK)1, Nemo-like Kinase (NLK), Siah2 E3 ubiquitin ligase or calcineurin-NFAT [21, 2528]. Reports describing activation of the canonical pathway by non-canonical WNT ligands also exist [21, 29] making WNT signaling difficult to decipher and even more difficult to modulate in cancer therapy.

Functional variations of WNT signaling among cell types

Functional analyses of the canonical and non-canonical WNT pathways revealed that the canonical, PCP and Ca2+ pathways regulate multiple cellular activities in the lung that are dependent on the specific cellular context. In most cell types, non-canonical WNT signaling regulates canonical WNT activity, which is also critical for many aspects of lung biology. In response to canonical WNT signaling for example, beta-catenin/TCF/LEF signaling is activated in different lung cell types including the primordial epithelium (PE), alveolar epithelium (AE), and adjacent mesenchyme [30]. Human tissue studies have highlighted that in the developing lung, beta-catenin is found mainly in the peripheral epithelium, LEF1 expression is detected in alveolar and bronchial epithelium, while TCF4 is observed in epithelium and mesenchyme [31]. Tissue-specific deletion of beta-catenin in lung epithelial cells of test animals led to disrupted lung morphogenesis, lack of differentiation of the peripheral lung, enhanced formation of the conducting airways and consequently to death at birth due to respiratory failure [32]. Furthermore, beta-catenin phosphorylation can also lead to respiratory defects. Phosphorylation of beta-catenin at tyrosine 489 stimulates its nuclear localization and fibroblast activation which is a characteristic feature of bronchopulmonary dysplasia [33]. While deletion of the non-canonical WNT5a causes hyper-thickening of the mesenchymal interstitium and over-branching of the epithelial airways [34], overexpression of WNT5a in the epithelium disrupts epithelial-mesenchymal interaction and causes malformations in both the airway epithelium and the surrounding mesenchyme [35]. WNT5a also has a role in epithelial-mesenchymal transition (EMT) in LC; where expression of WNT5a and its receptor FZD2 have an inverse correlation with the expression of markers of epithelial differentiation, such as EpCAM, E-cadherin or keratin. Expressions of WNT5a and FZD2 positively correlate with the expression of vimentin, N-cadherin and fibronectin, which are well-known mesenchymal markers and are used to identify EMT during carcinogenesis [36].
Consequently, constitutive activation of either the canonical or the non-canonical WNT pathways in the developing lung can result in non-differentiated, dysfunctional lung phenotypes that resemble certain subtypes of LCs [37]. In support of this, investigation of constitutive activation of beta-catenin has shown that hyperactive canonical WNT signaling may channel NSCLC carcinogenesis towards the adenocarcinoma subtype [38].

WNT signaling in LC

Various LC subtypes are believed to originate from stem cells in different histological parts of the lung. Adenocarcinoma, one of the NSCLC subtypes, has been reported to develop from various progenitor cells including alveolar type (AT) II cells, Clara cells, and bronchioalveolar stem cells (BASCs) [3941]. The other NSCLC subtype, squamous cell carcinoma, initiates from basal cells [42] whereas SCLC is derived from pulmonary neuroendocrine cells (PNECs) [43]. Studies using genetic manipulation, however, have proved that such “histologically localized stem cell origin” approaches in LC are oversimplified. Overexpression of RAS for example in PNECs, a cell type thought to be the origin of SCLC leads to adenocarcinoma [44], while inactivation of p53 and Rb1 in ATII cells results in SCLC instead of adenocarcinoma [45]. Such studies indicate that driver mutations are more important than the cell of origin.

Murine cancer models

In murine models, activation of WNT signaling is associated with increased carcinogenic potential [46] especially if activation of canonical WNT signaling is triggered parallel with KRAS mutation [47, 48]. This process is also observed in human LC [49]. In human lung adenocarcinoma cases KRAS mutations are missense mutations which introduce amino acid substitution at one of the positions 12, 13, or 61. The result of these mutations is constitutive activation of the KRAS signaling pathway and it has been shown that if activation of KRAS and WNT signaling are combined, the joint activation leads to increased tumor size [49]. While tumors in WNT1 transgenic mice regress as WNT signals are blocked, tumor growth becomes WNT-independent in p53-deficient mice [50]. In the KRAS G12D substitution induced lung adenocarcinoma mouse model, WNT signaling enhances proliferation and EMT. Also, if down-regulation of SOX2 and upregulation of SOX9 and GATA6 simultaneously accompany KRAS mutation [51] then alterations in WNT signaling do not modulate the final outcome [48].

WNT pathway mutations differ in LC from other cancer types

The most studied WNT pathway mutations in cancers include inherited and sporadic mutations in APC and beta-catenin genes. Since APC is part of the degradation scaffold for beta-catenin, mutations of APC result in reduced degradation and increased nuclear accumulation of beta-catenin, leading to activation of target oncogenes including cyclin D1 and c-myc [52]. Such mutations are not universal in all cancer types and while APC mutations occur more frequently in cancers of the colon, the lung is rarely affected by such mutations. A constitutively active beta-catenin-LEF1 fusion protein under tissue specific promoter control has been designed to express mutant, degradation-resistant beta-catenin to mimic the effect of mutation in the degradation scaffold [37]. The fusion protein was used to mimic the constitutive activation of beta-catenin which has also been described in cancers of the lung. Increased levels of beta-catenin [53, 54] and loss of heterozygosity on chromosome 5q, which contains the APC locus, have been observed in LC types (Table 1). While specific site mutations of the APC [55] or the beta-catenin genes are rare in LCs, LC types are much better characterized by dysregulation of WNT ligand transcription [5658]. For example, loss of WNT7a mRNA is a frequent feature of some LC cell lines and primary tumors [59]. NSCLC cells transformed with WNT7a show inhibition of anchorage independent growth via the JNK/AP1 dependent PCP signaling pathway [60]. In some other NSCLCs, elevated levels of WNT1 [61] and WNT2 [62] have been reported. Experimental inhibition of WNT2 induced signaling leads to down-regulation of the anti-apoptotic gene, Survivin and consequently initiates apoptosis [62]. The Sox2 gene coding the SOX2 transcription factor that is essential for maintaining self-renewal is also highly expressed in the main histological types of LCs [63]. Inhibition of SOX2 expression in lung adenocarcinoma induces apoptosis of tumor cells [64] and down-regulates WNT1/2, Notch1, and c-myc gene expression. On the other hand, stabilization of beta-catenin signaling blocks Clara cell differentiation to ciliated cells [65], while deletion of beta-catenin in basal cells is able to suppress proliferation and triggers apoptosis [66]. Moreover, autocrine insulin-like growth factor-I (IGF-I) signaling induces WNT5a dependent trans-differentiation of ATII cells to ATI-like cells [67].
Table 1
WNT ligands and signaling molecules associated with LC
Gene
Function
Mutation type/level of expression
References
APC
Part of beta-catenin destruction complex
No mutation
Suppressed expression by promoter methylation
[184]
AXIN
Negative regulator of WNT signaling. Promotes beta-catenin phosphorylation which leads to beta-catenin degradation
No mutation
Reduced expression
[185]
CTNNB1
Main component of canonical signaling, it serves as a transcription activator, binding to TCF/LEF family
Missense mutation of exon 3 results in substitution of Ser/Thr residues
[38]
 
No mutation
Increased expression in cytoplasm and nuclear compartment associated with poor prognosis
[186]
DKK1
Binding to LRP5/6 leads to its endocytosis and inhibition of canonical signaling
Increased expression detected in serum
[187]
DKK3
Secreted WNT antagonist
No mutation
Reduced expression
[188]
DVL1
Required for FZD induced signaling pathway activation
No mutation
Increased expression associated with advanced stages
[189]
DVL2
No mutation
Increased expression is associated with advanced stages
[189]
DVL3
No mutation
Increased expression
[190]
FZD8
Receptor for WNT proteins
No mutation
Increased expression
[191]
GSK-3-beta
Phosphorylates beta-catenin resulting in beta-catenin degradation
No mutation
Ser9 phosphorylation is associated with poor prognosis
[192]
SFRP1
Inhibits WNT signaling by binding to WNT proteins
No mutation
Reduced expression regulated by promoter hypermethylation
[193]
TCF4
Transcription factor that complexes with beta-catenin upon activated canonical WNT signaling
No mutation
Increased expression in poorly differentiated tumor
[194]
WIF1
Binding to WNT proteins to prevent their interaction with receptors
No mutation
Increased expression
[195]
WNT1
Non-canonical WNT ligand
No mutation
Increased expression in NSCLC
[196]
WNT11
WNT ligand which can activate both canonical and non-canonical WNT pathway
No mutation
Increased expression
[68]
WNT2
Canonical WNT ligand
No mutation
Increased expression
[197]
WNT3
Canonical WNT ligand
No mutation
Increased expression
[107]
WNT5A
Non-canonical WNT ligand
No mutation
Increased expression in SCC
[134]
WNT7A
Non-canonical WNT ligand
No mutation
Reduced expression due to promoter hypermethylation
[198]
WNT7B
Canonical WNT ligand
No mutation
Increased expression in AC
[199]
Most of the WNT pathway associated molecules are not mutated but the WNT signaling pathway is deregulated

Shifts between canonical and non-canonical WNT signaling modulate the carcinogenic process.

A shift from canonical to non-canonical WNT signaling, or vice versa, has also been reported in certain NSCLS subtypes. Up-regulation of the canonical WNT7b was detected in adenocarcinomas, while increased expression of WNT5a was found in primary squamous cell carcinomas [68]. Additionally, although the metastatic stage of any tumors are associated with EMT [69] and generally linked to increased beta-catenin-dependent signaling [70], the non-canonical WNT5a, which also regulates fibroblast growth factor (FGF) 10 and sonic hedgehog (SHH) expression [35], is overexpressed in lung metastases [71]. Matrix metalloproteinases, which are essential for tissue remodeling and are elevated in invasive cancers [72, 73], are target genes of both canonical and non-canonical WNT signaling pathways.
It is not only the WNT ligands, but also various signaling molecules that are dysregulated in LCs. For example, overexpression of DVL-3, a signal transducer molecule and positive regulator of WNT signaling pathways, was reported in 75% of primary NSCLCs compared to autologous matched normal tissue controls [74]. Down-regulation of WNT pathway antagonists, like Dickkopf-3 (DKK-3) [75], WNT inhibitory factor (WIF) [76, 77] and secreted Frizzled-Related Protein (sFRP) [78], have also been reported in various subtypes of LCs (summarized in Table 1).

Genome-wide association studies and LC susceptibility

Genome-wide association studies recently identified three LC susceptibility loci in chromosome regions 15q25, 5p15 and 6p21 [79]. Importantly, the nicotinic acetylcholine receptor (nAChR) subunit genes are located on the 15q25 chromosomal region. As nAChRs are expressed on bronchial cells and bind tobacco-related carcinogens with higher affinity than nicotine itself, therefore it is not surprising that the risk of LC is drastically increased in smokers [80]. Nicotinc AChRs in general, and alpha7 nAChRs in particular have been linked to nicotine-stimulated proliferation of lung carcinoma cells [81]. The nicotine induced up-regulation of WNT/PPAR-gamma (peroxisome proliferator activated receptor gamma) signaling can also regulate cigarette smoke-induced trans-differentiation of lung fibroblast to myofibroblasts that participate forming the cancer-associated stroma [82]. The BAT3 gene on the 6p21 locus affects p53 function and the cellular response to stress and apoptosis [83]. The same locus has also been associated with increased LC risk [80]. The telomerase reverse transcriptase (TERT) is located on the 5p15 locus and its modifications can cause aberrant proliferation and increased LC risk in both smokers and non-smokers [84]. The TERT-mediated developmental programs are similar to Myc and WNT-mediated responses and therefore, the increased risk for proliferative diseases is not surprising [84]. Interestingly, a genome-wide association study conducted on people who had never smoked revealed a strong correlation between the reduced transcription level of the glypican-5 (GPC5) gene and genotypes of the replicated SNP (rs2352028 at 13q31.3) in lung adenocarcinomas. GPC5 is a member of the glypican gene family of heparin sulphate proteoglycans that control the signaling pathway of WNT, hedgehog (HH), fibroblast growth factors (FGFs), and bone morphogenetic proteins (BMPs) which are all important regulators of cellular proliferation and differentiation [85].

WNT ligands are “posted” in lipid envelopes

Gradients of WNT proteins are essential for tissue maintenance. Importantly, WNT gradients lead to different gene expressions at certain points of the gradient in the tissue. Such concentration differences generated along the gradient might even explain how designated “canonical” and “non-canonical” WNT proteins can alternate between signaling pathways. How the gradient is maintained is not yet entirely clear. Due to their lipid residues, WNT proteins are highly hydrophobic; they attach tightly to cell membranes [86] and then insert themselves into the lipid bilayer. If the lipid residues are removed from the amino acid backbone, WNT proteins become biologically inactive [87]. Due to their lipid modifications, WNT ligands understandably cannot be directly secreted into aqueous body fluids (Fig. 2). Recent studies indicate that WNT signals are most likely to be transduced via lipid-coated particles including extracellular vesicles [88]. For decades, extracellular vesicles or exosomes have been disregarded as a potential route of cellular communication, but recently they have leaped into the center of interest. Lipid envelopes can influence long-range WNT signal gradients [89] via Reggie-1/flotillin-2 (FLOT2) [90], a major component of lipid microdomains in membranes that can promote WNT secretion and diffusion [91]. Recent studies have revealed that high FLOT2 expression both mRNA and protein level predict poor outcomes in NSCLC [92]. Such findings indicate that it is not just differential WNT expression but also WNT concentration at various points of its gradient, membrane availability of WNT ligands and endocytosis of specific WNT molecules can change during carcinogenesis, thus modulating cellular activity and potentially drug response.

Posttranslational modifications of WNT pathway molecules in regulation of LC

Secreted inhibitors and activators that regulate complex interactions within the complicated molecular network of WNT signaling [93] are under intense investigation. Epigenetic modulation, such as DNA methylation or histone deacetylation contributes to the deregulation of WNT signaling pathways. Down-regulation of several WNT signaling inhibitors have been reported in NSCLCs including AXIN, sFRPs 1–5, WIF-1, DKK-1, DKK-3, human homolog of Dapper (HDPR)1, runt-related transcription factor (RUNX)3, APC, caudal type homeobox (CDX)2, Dapper homolog (DACT)2, transmembrane protein (TMEM)88, Chibby, naked cuticle homolog (NKD1), empty spiracles homeobox (EMX)2, inhibitor of growth family (ING)4, and miR-487b. Although the mechanisms are not yet entirely clear, methylation and hypermethylation are the likely causes of reduced inhibitor levels [94, 95]. DACT 2 is one of the Dact gene family members, which inhibit canonical WNT signaling. If expression of DACT2 is lost due to hypermethylation of its promoter, then beta-catenin dependent signaling is no longer suppressed and uncontrollable proliferation ensues [96]. Similarly to DACT2, GPC5 is downregulated in lung adenocarcinomas due to significant promoter hypermethylation. The methylation level of GPC5 promoter negatively correlates with its transcriptional expression and beta-catenin dependent signaling [97]. Restoration of its WNT pathway inhibitory function results in reduced WNT signaling, decreased cell proliferation, and increased apoptosis. Apart from promoter methylation of WNT pathway inhibitors, methylation of the beta-catenin promoter has also been described that leads to loss of beta-catenin protein expression and a poor prognosis in NSCLC patients [98].
Epigenetic modulation of the “anti-aging” Klotho [99] is also significant in carcinogenesis [100102]. Klotho can act as an antagonist of the beta-catenin-dependent WNT signaling pathway; therefore overexpression of Klotho can reduce active beta-catenin and target c-myc and cyclin D1 levels [102], resulting in reduced proliferation. Supporting the above findings, down-regulation of Klotho increases cisplatin resistance while Klotho expression can attenuate resistance of LC to cisplatin-based chemotherapy and increase apoptosis [103]. Clinical survival analysis of various cancer types, however, has not demonstrated unequivocal involvement of Klotho in the carcinogenic process and it is still unclear whether the inconsistent role of Klotho in carcinogenesis is dependent on epigenetic variability or other factors [104, 105]. Recent discovery has exposed that apart from histone or DNA methylation of WNT signaling regulators, arginine methylation of the DVL-associated G3BP2 protein is a necessary post-translational modulation for LRP6 phosphorylation to initiate WNT3a induced canonical beta-catenin signaling from the receptor complex [106]. As WNT3a is one of the WNT ligands that promotes LC progression [107], investigation of methylation dependency of signaling molecules in the canonical signaling cascade can open up new therapeutic targets for drug discovery.
Methylation, however, is not the only posttranslational modification that modulates WNT signaling. AXIN, for example, can be destabilized by tankyrases [108] that regulate protein interactions and protein stability by poly-ADP-ribosylation. The post-translational modification of the N-terminal region of histone, by acetylation, methylation, ubiquitination, phosphorylation, or sumoylation, regulates DNA transcription, replication and repair. Recent epigenetic and transcriptomic profiling of human primary alveolar epithelial cells during in vitro differentiation revealed interactions amongst known regulatory pathways of distal alveolar epithelial cell differentiation. Interactions amongst the WNT signaling pathways, the transforming growth factor beta (TGF-beta) pathway, the hepatocyte nuclear factor 4 alpha (HNF4A) and the retinoid X receptor (RXR) signaling pathway [109] were strongly dependent on posttranslational changes.

MicroRNAs targeting WNT signaling and LC

The non-coding microRNAs or miRNAs suppress gene expressions by inhibiting translation or increasing degradation of target gene mRNAs [110]. miRNAs, similarly to WNT proteins and various lipophilic molecules are delivered to target cells mostly in extracellular vesicles that are shed into body fluids from a great variety of cells for secure “message” delivery. For diagnostic purposes, collecting cancer specific miRNAs from extracellular vesicles rather than serum is more reliable, as the extracellular vesicle protects miRNAs from degradation [111].
Several miRNAs have been identified in association with various types of LCs in recent years (Table 2). For example, down-regulation of miR-29 and let-7 were shown to be DNMT3A⁄3B [112] and KRAS [113] targeting miRNAs, respectively, allowing upregulation of their targets. Meanwhile, KRAS, MYC, WNT5a, BMI1, and SUZ12 are targeted by miR-487b, which is down-regulated in certain types of LCs supporting the carcinogenic process [114]. Down-regulation of miR-214 levels was documented in cancer stem cells (CSCs) leading to stem cell marker expression including Nanog, OCT4, and SOX2 [115]. Amongst miR-214 targets in lung adenocarcinomas several beta-catenin-interacting proteins were also found [115], while beta-catenin itself was rather affected by miR-3619-5p. miR-3619-5p has been documented to suppress tumor growth in A549 and H460 NSCLC cell lines via binding to the 3′-UPR region of the beta-catenin gene [116]. Additionally, overexpression of miR-376c inhibits the growth of NSCLC cells via a WNT-related orphan nuclear receptor, the liver receptor homolog-1 (LRH-1) [117].
Table 2
miRNAs regulating WNT signaling in LC
microRNA
Regulation
References
miR-34a
Inhibits beta-catenin activity
[200]
miR-17-92
Increases beta-catenin activity
[201]
miR-21
Increases beta-catenin expression
[202]
miR-27b
Upregulated by WNT5a, inhibits vascular branching
[134]
miR-29
Downregulates beta-catenin expression
[203]
miR-31
Decreases WNT antagonists and increases WNT5a
[119]
miR-191
Increases beta-catenin pathway activation
[204]
miR-374a
Targets WNT5a
[205]
miR-376c
Suppresses canonical WNT signaling
[117]
miR-410
Activates beta-catenin pathway
[118]
miR-487b
Reduces WNT5a activity
[114]
miR-544a
Downregulates GSK3beta
[206]
miR-574-5p
Enhances beta-catenin phosphorlyation
[207]
miR-708
Increases canonical WNT signaling
[208]
In contrast, miR-410 can accelerate tumor growth by suppressing the expression of SLC34A2, a type 2b sodium-dependent phosphate transporter (NaPi-IIb) that is located in the apical membrane of ATII cells. Decreased NaPi-IIb levels have been shown to activate the WNT/beta-catenin pathway leading to enhanced tumor growth and invasion [118]. Perhaps not surprisingly, miRNA expression is also regulated by one of the primary causes of LCs, cigarette smoke. miR-31 for example that targets the WNT pathway inhibitor DKK1 is triggered by cigarette smoke leading to enhanced tumorigenesis in the lung [119].
Although some miRNAs have not been directly associated with WNT signaling in NSCLCs, in other tumor types they have been demonstrated to play important WNT pathway regulatory function. For example miR-148b suppresses tumor growth via inhibiting canonical WNT signaling in hepatocellular carcinoma [120], while miR-499 can stimulate blood vessel formation via WNT signaling activation in various other tumor types [121]. Their precise role in LCs awaits further investigation.

WNT signaling in LC angiogenesis

WNT signaling has a fundamental role in both normal and tumor angiogenesis [122]. The canonical WNT pathway can regulate cadherin junctions in endothelial cell connections and therefore vascular permeability [123, 124]. Additionally, WNT signaling controls trans-endothelial migration of tumor cells via beta-catenin-dependent regulation of endothelial VE-, E- and N-cadherin expression [123125]. The WNT-Ca2+ pathway -which is often referred to as a pro-angiogenic signaling pathway- induces endothelial cell proliferation and enhances capillary network formation, while activation of the PCP WNT pathway coordinates endothelial cell migration [126]. Activation of the PCP pathway via FZD4 impairs vascular morphogenesis [127], while activation of downstream components, such as DAAM-1 can reverse the changes [126]. The WNT/PCP pathway is responsible for impaired pericyte motility and as pericytes are important components of vessel formation and integrity, the balance of WNT pathways are important in forming and maintaining a functional lung vasculature [128]. Any imbalances in canonical and non-canonical WNT signaling could, therefore, modulate blood vessel formation in tumors and consequently affect therapeutic responses.

Induction of neovascularization – Similarities and differences in LC subtypes

Cancer cells can induce neovascularization when the solid tumor reaches more than 2 mm in diameter [129] and hypoxia occurs in the inner center of the tumor. Intra-tumor angiogenesis is best characterized by microvessel density. Extensive vascularization and higher vessel density indicate disease progression and predict a poor outcome in NSCLCs [130]. Amongst several other pro-angiogenic factors like Hypoxia-Inducible Factor (HIF)1alpha [131], Vascular Endothelial Growth Factor (VEGF)-A is of vital importance for endothelial cell proliferation and motility [132]. The pro-angiogenic factors are under complex molecular regulation. VEGF-A for example is documented to be under beta-catenin-dependent, canonical WNT control via a PPAR-gamma dependent mechanism [133]. Interestingly, PPAR-gamma down-regulation that is essential for VEGF-A up-regulation, can also be induced by a WNT5a triggered miR27b dependent manner [134]. Although tumors including NSCLC subtypes use the same molecular components to attract the necessary cell types for blood vessel formation as normal tissues, tumor vessels are often leaky, poorly differentiated and not hierarchic. This is due to differential WNT expression induced modulation of cellular morphology and function leading even to cellular mimicry of cells in the resident vascular network [135, 136]. For instance, WNT5a signaling can induce vascular mimicry [137], while canonical pathway activation by WNT3a or WNT7b is associated with increased angiogenesis [138, 139].

Angiogenesis and WNT target genes: Matrix metalloproteinases

The canonical WNT pathway mediated EMT [140], which correlates with E-cadherin down-regulation [68] and VEGF-A up-regulation is associated with micrometastasis formation [141, 142]. Blood vessel formation in lung tumors, however, also need the WNT target proteolytic matrix metalloproteinase enzymes (MMPs) [143] that are responsible for degradation of the extracellular matrix components during new blood vessel formation or vessel branching. MMP-2, −3, −7 and MMP-9 have been shown to be important in NSCLCs [93] and angiogenesis in general [143]. One of the most studied enzymes is MMP-9 which degrades type IV collagen, modulates VEGF bioavailability through direct cleavage and also regulates vascular permeability [144]. In lung adenocarcinomas, MMP-9 levels correlate with increased risk of relapse [143, 145], although its direct regulation by canonical WNT3a signaling has only been studied in colorectal cancer [146]. MMP-7 is up-regulated by canonical WNT signaling and associated with increased invasion of LCs [147149]. Additionally, up-regulation of MMP1 by the non-canonical WNT5a has also been shown in NSCLC [137]. Proteomic analysis of an Mmp1−/− mouse model revealed that tumor growth is hampered by the absence of MMP1 activity and is also associated with decreased levels of chitinase-3 like 3 (CHI3L3) and accumulation of the receptor for advanced glycation end-products (RAGE) and its ligand, S100A8 [150]. The molecules identified in the mouse model are important markers for lung development, aging and tumorigenesis. Upregulation of RAGE, for example, is observed in type I alveolar epithelial cells (ATI) during lung development, which process is associated with reduced beta-catenin-dependent WNT signaling [151]. Interestingly, during aging RAGE is highly expressed [152], while in malignant lung tumors RAGE is down-regulated [153, 154]. More studies are needed to explain such differences and to identify the primary role of RAGE in aging normal lung tissue and in LC.

The angiogenic process as a therapeutic target

As the angiogenic process is a therapeutic target in solid tumors, anti-angiogenic agents have become important in therapy. The anti-VEGF-A monoclonal antibody, bevacizumab is the first approved antiangiogenic agent to be applied in NSCLSs [155]. Despite some success of anti-angiogenic agents in cancer treatment, the expected break-through in cancer therapy has not occurred. A randomized phase II study investigated the effect of bevacizumab mono- and paclitaxel-carboplatin-bevacizumab combination therapy. Although the latter combination increased progression free survival, serious hemorrhage was detected in some patients mostly with squamous histology [156]. As there is a well-documented difference in the WNT ligand profile of the two NSCLC subtypes [68], further studies of WNT controlled regulation of blood vessel formation is needed to more effectively stratify patients for the most appropriate anti-angiogenic treatment. The most worrying aspect is that in some cases – mostly in glioblastomas [157160] - administration of anti-angiogenic drugs contributed to formation of even more invasive tumors and failure of cytotoxic treatment.

Maintenance of cancer stem cells and therapeutic resistance

The accumulation of highly chemotherapy resistant cancer stem cells (CSC) are thought to play an important role in the incurability of LCs [161]. In CSCs beta-catenin dependent canonical WNT signaling is highly active and helps to maintain CSCs that express putative stem cell markers such as octamer-binding transcription factor 4 (OCT4) [162], Leucine-Rich Repeat-containing G-protein coupled receptor 5 (LGR5/GPR49), CD44, CD24, EpCAM [163], and cyclin D1 [11, 162]. The above markers are associated with increased cell proliferation rate and clone formation efficacy [164]. Such CSCs are highly resistant to several chemotherapeutic drugs [164] due to overexpression of ATP-binding cassette (ABC) transporter protein G2 (ABCG2 or BCRP1) [165, 166] resulting in increased drug efflux [167]. Apart from ABCG2 the presence of other ATP-binding cassette (ABC) transporter family members, such as ABCB1 (MDR1 or Pgp) are frequently tested as they are responsible for chemotherapeutic drug removal from cancer cells. Recently, the canonical WNT pathway dependent beta-catenin target TCF/LEF transcription factors were shown to activate the ABCB1 promoter indicating that WNT signaling is involved in the regulation of efflux transporter expression [168]. Studies of ABCB1 revealed that paclitaxel and irinotecan - the two drugs often used in cisplatin or carboplatin combination therapy of LCs [169, 170] - are both substrates of ABCB1. Cisplatin, a widely used drug in LC therapy, can also activate the canonical WNT pathway [162] which may explain the increased expression of efflux drug transporters including ABCB1 and ABCG2 correlating with reduced survival of NSCLC [171] and SCLC patients [172]. In contrast, inhibition of the beta-catenin dependent WNT pathway by high serum levels of the canonical pathway inhibitor DKK1 [173] has been detected in patients suffering from NSCLC and esophageal carcinoma. Increase in DKK1 levels was also associated with resistance to platina-based chemotherapy [174]. Based on previous research data, the role of WNT signaling in ABC transporter regulation appears contradictory, therefore more studies are needed to understand the molecular regulation and to identify potential therapeutic targets in WNT pathway associated chemoresistance.
Although increased expression of drug transporters in chemoresistant lung tumors suggests that the drug transporters might be useful therapeutic targets, sadly, clinical trials using ABC transporter inhibitors have not been successful. For example, the ABCB1 (MDR1) inhibitors tariquidar and CBT-1(R) [175177] were tested unsuccessfully in two phase III clinical studies where treatment of stage IIIB/IV NSCLC patients with tariquidar in combination with vinorelbine or carboplatin/paclitaxel did not show any advantages and the trial was finished prematurely (ID NCT00042302 and NCT00042315) [178]. Additionally, inhibitors of efflux transporters can seriously damage the non-cancerous stem cell pool by increasing toxicity and enhancing the serious side effects of such therapies [179].

Conclusions

Complex deregulation of WNT signaling is an important element of lung carcinogenesis, controlling not just the carcinogenic process, but also tumor vascularization, drug response and disease progression. While current cancer research frequently cites the importance of precision medicine, therapeutic approaches and even drug development are still strongly focused on genetic mutations [180]. Individual variations in genetic driver and passenger mutations, along with non-mutated but deregulated signaling pathway combinations receive less attention, but can be just as important. Novel drugs are therefore under development to interfere with molecules of the WNT signaling pathway. Recently, NSCLC patients have been recruited into a clinical trial (NCT01957007) testing an anti-FZD7 antibody (OMP18R5 or Vantictumab) in combination therapy [181]. Further studies, however, are also needed to show the effect of WNT pathway interference on tumor cells and non-tumor cells alike [182]. The WNT-receiving cells respond to WNT proteins in a concentration-dependent manner by activating different target genes. Simply, blocking a receptor therefore may result in different cellular response in tumor cells and non-tumor cells at various points of the WNT ligand concentration gradient. To understand such complexity, experimental models of human cancer tissues [183] are essential for future studies. This will allow us to expand our understanding of carcinogenesis beyond mutation analysis and allow intricate investigation of the tissue microenvironment and its effect on epigenetic signal modulation in carcinogenesis and therapeutic drug response.

Acknowledgements

The authors are indebted to Prof Emerita Mary Keen, Department of Pharmacy and Therapeutics, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, UK and Mr. Ricky Odedra, University of Pecs, Hungary for discussions and language editing.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Funding

JEP was supported by the European Union and the State of Hungary, co-financed by the European Social Fund in the framework of TÁMOP-4.2.4.A/2–11/1–2012-0001 ‘National Excellence Program’.
This work was also supported by the GINOP 2.3.2–15–2016-00022 grant. The project has been supported by the European Union, co-financed by the European Regional Development Fund.
Not applicable.

Competing interests

The author(s) declare(s) that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
2.
14.
15.
Zurück zum Zitat Lu W, Yamamoto V, Ortega B, Baltimore D. Mammalian Ryk is a WNT Coreceptor required for stimulation of neurite outgrowth. Cell. 2004;119:97–108.CrossRefPubMed Lu W, Yamamoto V, Ortega B, Baltimore D. Mammalian Ryk is a WNT Coreceptor required for stimulation of neurite outgrowth. Cell. 2004;119:97–108.CrossRefPubMed
17.
Zurück zum Zitat Bentzinger CF, von Maltzahn J, Dumont NA, Stark DA, Wang YX, Nhan K, et al. WNT7a stimulates myogenic stem cell motility and engraftment resulting in improved muscle strength. J Cell Biol. 2014;205 Bentzinger CF, von Maltzahn J, Dumont NA, Stark DA, Wang YX, Nhan K, et al. WNT7a stimulates myogenic stem cell motility and engraftment resulting in improved muscle strength. J Cell Biol. 2014;205
18.
Zurück zum Zitat Movérare-Skrtic S, Henning P, Liu X, Nagano K, Saito H, Börjesson AE, et al. Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures. Nat. Med. [Internet]. 2014 [cited 2016 Jun 14];20:1279–1288. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25306233. Movérare-Skrtic S, Henning P, Liu X, Nagano K, Saito H, Börjesson AE, et al. Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures. Nat. Med. [Internet]. 2014 [cited 2016 Jun 14];20:1279–1288. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25306233.
20.
Zurück zum Zitat Wang Y. WNT/planar cell polarity signaling: a new paradigm for cancer therapy. Mol Cancer Ther. 2009;8 Wang Y. WNT/planar cell polarity signaling: a new paradigm for cancer therapy. Mol Cancer Ther. 2009;8
22.
26.
Zurück zum Zitat Ishitani T, Kishida S, Hyodo-Miura J, Ueno N, Yasuda J, Waterman M, et al. The TAK1-NLK mitogen-activated protein kinase cascade functions in the WNT-5a/Ca(2+) pathway to antagonize WNT/beta-catenin signaling. Mol. Cell. Biol. [Internet]. 2003 [cited 2016 Jun 14];23:131–139. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12482967. Ishitani T, Kishida S, Hyodo-Miura J, Ueno N, Yasuda J, Waterman M, et al. The TAK1-NLK mitogen-activated protein kinase cascade functions in the WNT-5a/Ca(2+) pathway to antagonize WNT/beta-catenin signaling. Mol. Cell. Biol. [Internet]. 2003 [cited 2016 Jun 14];23:131–139. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​12482967.
27.
32.
Zurück zum Zitat Mucenski ML, Wert SE, Nation JM, Loudy DE, Huelsken J, Birchmeier W, et al. beta-Catenin is required for specification of proximal/distal cell fate during lung morphogenesis. J. Biol. Chem. [Internet]. American Society for Biochemistry and Molecular Biology; 2003 [cited 2017 Apr 11];278:40231–40238. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12885771. Mucenski ML, Wert SE, Nation JM, Loudy DE, Huelsken J, Birchmeier W, et al. beta-Catenin is required for specification of proximal/distal cell fate during lung morphogenesis. J. Biol. Chem. [Internet]. American Society for Biochemistry and Molecular Biology; 2003 [cited 2017 Apr 11];278:40231–40238. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​12885771.
33.
Zurück zum Zitat Sucre JMS, Vijayaraj P, Aros CJ, Wilkinson D, Paul M, Dunn B, et al. Posttranslational modification of β-catenin is associated with pathogenic fibroblastic changes in bronchopulmonary dysplasia. Am. J. Physiol. - Lung Cell. Mol. Physiol. [Internet]. 2017 [cited 2017 May 4];312 Available from: http://ajplung.physiology.org/content/312/2/L186 Sucre JMS, Vijayaraj P, Aros CJ, Wilkinson D, Paul M, Dunn B, et al. Posttranslational modification of β-catenin is associated with pathogenic fibroblastic changes in bronchopulmonary dysplasia. Am. J. Physiol. - Lung Cell. Mol. Physiol. [Internet]. 2017 [cited 2017 May 4];312 Available from: http://​ajplung.​physiology.​org/​content/​312/​2/​L186
38.
Zurück zum Zitat Sunaga N, Kohno T, Kolligs FT, Fearon ER, Saito R, Yokota J. Constitutive activation of the WNT signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer [Internet]. 2001 [cited 2017 may 4];30:316–321. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11170292. Sunaga N, Kohno T, Kolligs FT, Fearon ER, Saito R, Yokota J. Constitutive activation of the WNT signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer [Internet]. 2001 [cited 2017 may 4];30:316–321. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​11170292.
41.
42.
43.
Zurück zum Zitat Song H, Yao E, Lin C, Gacayan R, Chen M-H, Chuang P-T. Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis. Proc Natl Acad Sci U S A. [Internet]. 2012 [cited 2016 Jun 14];109:17531–17536. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23047698. Song H, Yao E, Lin C, Gacayan R, Chen M-H, Chuang P-T. Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis. Proc Natl Acad Sci U S A. [Internet]. 2012 [cited 2016 Jun 14];109:17531–17536. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23047698.
45.
Zurück zum Zitat Sutherland KD, Proost N, Brouns I, Adriaensen D, Song J-Y, Berns A. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell [Internet]. 2011 [cited 2016 Jun 14];19:754–764. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21665149. Sutherland KD, Proost N, Brouns I, Adriaensen D, Song J-Y, Berns A. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell [Internet]. 2011 [cited 2016 Jun 14];19:754–764. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​21665149.
46.
Zurück zum Zitat Vaughan AE, Halbert CL, Wootton SK, Miller AD. Lung cancer in mice induced by the jaagsiekte sheep retrovirus envelope protein is not maintained by rare cancer stem cells, but tumorigenicity does correlate with WNT pathway activation. Mol. Cancer Res. [Internet]. 2012 [cited 2016 Jun 14];10:86–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22064658. Vaughan AE, Halbert CL, Wootton SK, Miller AD. Lung cancer in mice induced by the jaagsiekte sheep retrovirus envelope protein is not maintained by rare cancer stem cells, but tumorigenicity does correlate with WNT pathway activation. Mol. Cancer Res. [Internet]. 2012 [cited 2016 Jun 14];10:86–95. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​22064658.
48.
Zurück zum Zitat Pacheco-Pinedo EC, Durham AC, Stewart KM, Goss AM, Lu MM, Demayo FJ, et al. WNT/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J. Clin. Invest. [Internet]. 2011 [cited 2016 Jun 14];121:1935–1945. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21490395. Pacheco-Pinedo EC, Durham AC, Stewart KM, Goss AM, Lu MM, Demayo FJ, et al. WNT/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J. Clin. Invest. [Internet]. 2011 [cited 2016 Jun 14];121:1935–1945. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​21490395.
52.
Zurück zum Zitat Venesio T, Balsamo A, Scordamaglia A, Bertolaso M, Arrigoni A, Sprujevnik T, et al. Germline APC mutation on the beta-catenin binding site is associated with a decreased apoptotic level in colorectal adenomas. Mod. Pathol. [Internet]. 2003 [cited 2016 Jun 14];16:57–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12527714. Venesio T, Balsamo A, Scordamaglia A, Bertolaso M, Arrigoni A, Sprujevnik T, et al. Germline APC mutation on the beta-catenin binding site is associated with a decreased apoptotic level in colorectal adenomas. Mod. Pathol. [Internet]. 2003 [cited 2016 Jun 14];16:57–65. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​12527714.
53.
Zurück zum Zitat Kotsinas A, Evangelou K, Zacharatos P, Kittas C, Gorgoulis VG. Proliferation, but not apoptosis, is associated with distinct beta-catenin expression patterns in non-small-cell lung carcinomas: relationship with adenomatous polyposis coli and G(1)-to S-phase cell-cycle regulators. Am. J. Pathol. [Internet]. 2002 [cited 2016 Jun 14];161:1619–1634. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12414510. Kotsinas A, Evangelou K, Zacharatos P, Kittas C, Gorgoulis VG. Proliferation, but not apoptosis, is associated with distinct beta-catenin expression patterns in non-small-cell lung carcinomas: relationship with adenomatous polyposis coli and G(1)-to S-phase cell-cycle regulators. Am. J. Pathol. [Internet]. 2002 [cited 2016 Jun 14];161:1619–1634. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​12414510.
57.
Zurück zum Zitat Ueda M, Gemmill RM, West J, Winn R, Sugita M, Tanaka N, et al. Mutations of the beta- and gamma-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer [Internet]. 2001 [cited 2016 Jun 14];85:64–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11437403. Ueda M, Gemmill RM, West J, Winn R, Sugita M, Tanaka N, et al. Mutations of the beta- and gamma-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer [Internet]. 2001 [cited 2016 Jun 14];85:64–68. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​11437403.
58.
Zurück zum Zitat Blanco D, Vicent S, Elizegi E, Pino I, Fraga MF, Esteller M, et al. Altered expression of adhesion molecules and epithelial-mesenchymal transition in silica-induced rat lung carcinogenesis. Lab Invest. [Internet]. 2004 [cited 2016 Jun 14];84:999–1012. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15195114. Blanco D, Vicent S, Elizegi E, Pino I, Fraga MF, Esteller M, et al. Altered expression of adhesion molecules and epithelial-mesenchymal transition in silica-induced rat lung carcinogenesis. Lab Invest. [Internet]. 2004 [cited 2016 Jun 14];84:999–1012. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15195114.
60.
Zurück zum Zitat Winn RA, Marek L, Han S-Y, Rodriguez K, Rodriguez N, Hammond M, et al. Restoration of WNT-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem [Internet]. 2005 [cited 2016 Jun 14];280:19625–19634. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15705594. Winn RA, Marek L, Han S-Y, Rodriguez K, Rodriguez N, Hammond M, et al. Restoration of WNT-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem [Internet]. 2005 [cited 2016 Jun 14];280:19625–19634. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15705594.
62.
63.
Zurück zum Zitat Chen S, Xu Y, Chen Y, Li X, Mou W, Wang L, et al. SOX2 Gene Regulates the Transcriptional Network of Oncogenes and Affects Tumorigenesis of Human Lung Cancer Cells. Tao Q, editor. PLoS One [Internet]. Public Library of Science; 2012 [cited 2016 Jun 14];7:e36326 Available from: http://dx.plos.org/10.1371/journal.pone.0036326 Chen S, Xu Y, Chen Y, Li X, Mou W, Wang L, et al. SOX2 Gene Regulates the Transcriptional Network of Oncogenes and Affects Tumorigenesis of Human Lung Cancer Cells. Tao Q, editor. PLoS One [Internet]. Public Library of Science; 2012 [cited 2016 Jun 14];7:e36326 Available from: http://​dx.​plos.​org/​10.​1371/​journal.​pone.​0036326
64.
Zurück zum Zitat Nakatsugawa M, Takahashi A, Hirohashi Y, Torigoe T, Inoda S, Murase M, et al. SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity. Lab Invest [Internet]. 2011 [cited 2016 Jun 14];91:1796–1804. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21931300. Nakatsugawa M, Takahashi A, Hirohashi Y, Torigoe T, Inoda S, Murase M, et al. SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity. Lab Invest [Internet]. 2011 [cited 2016 Jun 14];91:1796–1804. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​21931300.
67.
Zurück zum Zitat Ghosh MC, Gorantla V, Makena PS, Luellen C, Sinclair SE, Schwingshackl A, et al. Insulin-like growth factor-I stimulates differentiation of ATII cells to ATI-like cells through activation of WNT5a. Am J Physiol Lung Cell Mol Physiol. [Internet]. 2013 [cited 2016 Jun 14];305:L222–L228. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23709620. Ghosh MC, Gorantla V, Makena PS, Luellen C, Sinclair SE, Schwingshackl A, et al. Insulin-like growth factor-I stimulates differentiation of ATII cells to ATI-like cells through activation of WNT5a. Am J Physiol Lung Cell Mol Physiol. [Internet]. 2013 [cited 2016 Jun 14];305:L222–L228. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23709620.
69.
Zurück zum Zitat Taki M, Kamata N, Yokoyama K, Fujimoto R, Tsutsumi S, Nagayama M. Down-regulation of WNT-4 and up-regulation of WNT-5a expression by epithelial-mesenchymal transition in human squamous carcinoma cells. Cancer Sci. [Internet]. 2003 [cited 2016 Jun 14];94:593–597. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12841867. Taki M, Kamata N, Yokoyama K, Fujimoto R, Tsutsumi S, Nagayama M. Down-regulation of WNT-4 and up-regulation of WNT-5a expression by epithelial-mesenchymal transition in human squamous carcinoma cells. Cancer Sci. [Internet]. 2003 [cited 2016 Jun 14];94:593–597. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​12841867.
70.
Zurück zum Zitat Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs [Internet]. 2005 [cited 2016 Jun 14];179:56–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15942193. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs [Internet]. 2005 [cited 2016 Jun 14];179:56–65. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15942193.
71.
Zurück zum Zitat Nakano T, Tani M, Ishibashi Y, Kimura K, Park Y-B, Imaizumi N, et al. Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin Exp Metastasis [Internet]. 2003 [cited 2016 Jun 14];20:665–674. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14669798. Nakano T, Tani M, Ishibashi Y, Kimura K, Park Y-B, Imaizumi N, et al. Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin Exp Metastasis [Internet]. 2003 [cited 2016 Jun 14];20:665–674. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​14669798.
72.
Zurück zum Zitat Kossakowska AE, Huchcroft SA, Urbanski SJ, Edwards DR. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin’s lymphomas in humans. Br J Cancer [Internet]. 1996 [cited 2016 Jun 14];73:1401–1408. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8645587. Kossakowska AE, Huchcroft SA, Urbanski SJ, Edwards DR. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin’s lymphomas in humans. Br J Cancer [Internet]. 1996 [cited 2016 Jun 14];73:1401–1408. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​8645587.
76.
Zurück zum Zitat Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, et al. WIF1, a component of the WNT pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol [Internet]. 2003 [cited 2016 Jun 14];201:204–212. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14517837. Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, et al. WIF1, a component of the WNT pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol [Internet]. 2003 [cited 2016 Jun 14];201:204–212. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​14517837.
78.
79.
Zurück zum Zitat Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Rotunno M, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet [Internet]. Elsevier; 2009 [cited 2017 may 5];85:679–691. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19836008. Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Rotunno M, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet [Internet]. Elsevier; 2009 [cited 2017 may 5];85:679–691. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​19836008.
81.
83.
Zurück zum Zitat Sasaki T, Gan EC, Wakeham A, Kornbluth S, Mak TW, Okada H. HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53. Genes Dev. [Internet]. Cold Spring Harbor Laboratory Press; 2007 [cited 2017 may 5];21:848–861. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17403783. Sasaki T, Gan EC, Wakeham A, Kornbluth S, Mak TW, Okada H. HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53. Genes Dev. [Internet]. Cold Spring Harbor Laboratory Press; 2007 [cited 2017 may 5];21:848–861. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​17403783.
84.
Zurück zum Zitat Choi J, Southworth LK, Sarin KY, Venteicher AS, Ma W, Chang W, et al. TERT Promotes Epithelial Proliferation through Transcriptional Control of a Myc- and WNT-Related Developmental Program. PLoS Genet. [Internet]. Public Library of Science; 2008 [cited 2017 May 5];4:e10 Available from: http://dx.plos.org/10.1371/journal.pgen.0040010 Choi J, Southworth LK, Sarin KY, Venteicher AS, Ma W, Chang W, et al. TERT Promotes Epithelial Proliferation through Transcriptional Control of a Myc- and WNT-Related Developmental Program. PLoS Genet. [Internet]. Public Library of Science; 2008 [cited 2017 May 5];4:e10 Available from: http://​dx.​plos.​org/​10.​1371/​journal.​pgen.​0040010
91.
Zurück zum Zitat Katanaev VL, Solis GP, Hausmann G, Buestorf S, Katanayeva N, Schrock Y, et al. Reggie-1/flotillin-2 promotes secretion of the long-range signalling forms of Wingless and Hedgehog in Drosophila. EMBO J. [Internet]. 2008 [cited 2016 Oct 20];27:509–521. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18219274. Katanaev VL, Solis GP, Hausmann G, Buestorf S, Katanayeva N, Schrock Y, et al. Reggie-1/flotillin-2 promotes secretion of the long-range signalling forms of Wingless and Hedgehog in Drosophila. EMBO J. [Internet]. 2008 [cited 2016 Oct 20];27:509–521. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​18219274.
92.
Zurück zum Zitat Wang Y-L, Yao W-J, Guo L, Xi H-F, Li S-Y, Wang Z-M. Expression of flotillin-2 in human non-small cell lung cancer and its correlation with tumor progression and patient survival. Int J Clin Exp Pathol. [Internet]. 2015 [cited 2016 Oct 20];8:601–607. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25755751. Wang Y-L, Yao W-J, Guo L, Xi H-F, Li S-Y, Wang Z-M. Expression of flotillin-2 in human non-small cell lung cancer and its correlation with tumor progression and patient survival. Int J Clin Exp Pathol. [Internet]. 2015 [cited 2016 Oct 20];8:601–607. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25755751.
96.
Zurück zum Zitat Wang S, Dong Y, Zhang Y, Wang X, Xu L, Yang S, et al. DACT2 is a functional tumor suppressor through inhibiting WNT/β-catenin pathway and associated with poor survival in colon cancer. Oncogene [Internet]. 2015 [cited 2016 Jun 14];34:2575–2585. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25023701. Wang S, Dong Y, Zhang Y, Wang X, Xu L, Yang S, et al. DACT2 is a functional tumor suppressor through inhibiting WNT/β-catenin pathway and associated with poor survival in colon cancer. Oncogene [Internet]. 2015 [cited 2016 Jun 14];34:2575–2585. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25023701.
97.
Zurück zum Zitat Yuan S, Yu Z, Liu Q, Zhang M, Xiang Y, Wu N, et al. GPC5, a novel epigenetically silenced tumor suppressor, inhibits tumor growth by suppressing WNT/β-catenin signaling in lung adenocarcinoma. Oncogene [Internet]. 2016 [cited 2016 Jun 14]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27157618. Yuan S, Yu Z, Liu Q, Zhang M, Xiang Y, Wu N, et al. GPC5, a novel epigenetically silenced tumor suppressor, inhibits tumor growth by suppressing WNT/β-catenin signaling in lung adenocarcinoma. Oncogene [Internet]. 2016 [cited 2016 Jun 14]; Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27157618.
98.
Zurück zum Zitat Miao Y, Wang L, Zang X, Xu X, Jiang G, Fan C, Liu Y, Lin X, Yu J, Zhang Y, Wang E. Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis. PLoS One. Public Library of Science. 2014;9 Miao Y, Wang L, Zang X, Xu X, Jiang G, Fan C, Liu Y, Lin X, Yu J, Zhang Y, Wang E. Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis. PLoS One. Public Library of Science. 2014;9
102.
Zurück zum Zitat Chen B, Ma X, Liu S, Zhao W, Wu J. Inhibition of lung cancer cells growth, motility and induction of apoptosis by Klotho, a novel secreted WNT antagonist, in a dose-dependent manner. Cancer Biol Ther [Internet]. 2012 [cited 2016 Jun 14];13:1221–1228. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22922788. Chen B, Ma X, Liu S, Zhao W, Wu J. Inhibition of lung cancer cells growth, motility and induction of apoptosis by Klotho, a novel secreted WNT antagonist, in a dose-dependent manner. Cancer Biol Ther [Internet]. 2012 [cited 2016 Jun 14];13:1221–1228. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​22922788.
104.
Zurück zum Zitat Usuda J, Ichinose S, Ishizumi T, Ohtani K, Inoue T, Saji H, et al. Klotho is a novel biomarker for good survival in resected large cell neuroendocrine carcinoma of the lung. Lung Cancer [Internet]. 2011 [cited 2016 Jun 14];72:355–359. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21075474. Usuda J, Ichinose S, Ishizumi T, Ohtani K, Inoue T, Saji H, et al. Klotho is a novel biomarker for good survival in resected large cell neuroendocrine carcinoma of the lung. Lung Cancer [Internet]. 2011 [cited 2016 Jun 14];72:355–359. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​21075474.
105.
Zurück zum Zitat Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer [Internet]. 2001 [cited 2016 Jun 14];91:1992–2000. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11391577. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer [Internet]. 2001 [cited 2016 Jun 14];91:1992–2000. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​11391577.
109.
Zurück zum Zitat Marconett CN, Zhou B, Rieger ME, Selamat SA, Dubourd M, Fang X, et al. Integrated transcriptomic and epigenomic analysis of primary human lung epithelial cell differentiation. PLoS Genet. [Internet]. 2013 [cited 2016 Jun 14];9:e1003513. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23818859. Marconett CN, Zhou B, Rieger ME, Selamat SA, Dubourd M, Fang X, et al. Integrated transcriptomic and epigenomic analysis of primary human lung epithelial cell differentiation. PLoS Genet. [Internet]. 2013 [cited 2016 Jun 14];9:e1003513. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23818859.
111.
Zurück zum Zitat Cheng L, Sharples RA, Scicluna BJ, Hill AF. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell. vesicles [Internet]. 2014 [cited 2016 Oct 20];3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24683445. Cheng L, Sharples RA, Scicluna BJ, Hill AF. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell. vesicles [Internet]. 2014 [cited 2016 Oct 20];3. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​24683445.
112.
Zurück zum Zitat Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. [Internet]. 2007 [cited 2016 Jun 14];104:15805–15810. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17890317. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. [Internet]. 2007 [cited 2016 Jun 14];104:15805–15810. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​17890317.
114.
Zurück zum Zitat Xi S, Xu H, Shan J, Tao Y, Hong JA, Inchauste S, et al. Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis. J Clin Invest [Internet]. 2013 [cited 2016 Nov 22];123:1241–1261 Available from: http://www.jci.org/articles/view/61271 Xi S, Xu H, Shan J, Tao Y, Hong JA, Inchauste S, et al. Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis. J Clin Invest [Internet]. 2013 [cited 2016 Nov 22];123:1241–1261 Available from: http://​www.​jci.​org/​articles/​view/​61271
115.
Zurück zum Zitat Qi W, Chen J, Cheng X, Huang J, Xiang T, Li Q, et al. Targeting the WNT-Regulatory Protein CTNNBIP1 by microRNA-214 Enhances the Stemness and Self-Renewal of Cancer Stem-Like Cells in Lung Adenocarcinomas. Stem Cells [Internet]. 2015 [cited 2016 Jun 14];33:3423–3436. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26299367. Qi W, Chen J, Cheng X, Huang J, Xiang T, Li Q, et al. Targeting the WNT-Regulatory Protein CTNNBIP1 by microRNA-214 Enhances the Stemness and Self-Renewal of Cancer Stem-Like Cells in Lung Adenocarcinomas. Stem Cells [Internet]. 2015 [cited 2016 Jun 14];33:3423–3436. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​26299367.
117.
Zurück zum Zitat Jiang W, Tian Y, Jiang S, Liu S, Zhao X, Tian D. MicroRNA-376c suppresses non-small-cell lung cancer cell growth and invasion by targeting LRH-1-mediated WNT signaling pathway. Commun: Biochem. Biophys. Res; 2016. Jiang W, Tian Y, Jiang S, Liu S, Zhao X, Tian D. MicroRNA-376c suppresses non-small-cell lung cancer cell growth and invasion by targeting LRH-1-mediated WNT signaling pathway. Commun: Biochem. Biophys. Res; 2016.
118.
119.
Zurück zum Zitat Xi S, Yang M, Tao Y, Xu H, Shan J, Inchauste S, et al. Cigarette smoke induces C/EBP-β-mediated activation of miR-31 in normal human respiratory epithelia and lung cancer cells. PLoS One [Internet]. Public Library of Science; 2010 [cited 2016 Nov 22];5:e13764. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21048943. Xi S, Yang M, Tao Y, Xu H, Shan J, Inchauste S, et al. Cigarette smoke induces C/EBP-β-mediated activation of miR-31 in normal human respiratory epithelia and lung cancer cells. PLoS One [Internet]. Public Library of Science; 2010 [cited 2016 Nov 22];5:e13764. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​21048943.
120.
Zurück zum Zitat Zhang J, Shi Y, Hong D, Song M, Huang D, Wang C, et al. MiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/β-catenin pathway. Sci Rep. [Internet]. Nature Publishing Group; 2015 [cited 2016 Oct 20];5:8087 Available from: http://www.nature.com/articles/srep08087 Zhang J, Shi Y, Hong D, Song M, Huang D, Wang C, et al. MiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/β-catenin pathway. Sci Rep. [Internet]. Nature Publishing Group; 2015 [cited 2016 Oct 20];5:8087 Available from: http://​www.​nature.​com/​articles/​srep08087
121.
Zurück zum Zitat Okamoto A, Asai T, Ryu S, Ando H, Maeda N, Dewa T, et al. Enhanced Efficacy of Doxorubicin by microRNA-499-Mediated Improvement of Tumor Blood Flow. J Clin Med. [Internet]. Multidisciplinary Digital Publishing Institute; 2016 [cited 2016 Oct 20];5:10 Available from: http://www.mdpi.com/2077-0383/5/1/10 Okamoto A, Asai T, Ryu S, Ando H, Maeda N, Dewa T, et al. Enhanced Efficacy of Doxorubicin by microRNA-499-Mediated Improvement of Tumor Blood Flow. J Clin Med. [Internet]. Multidisciplinary Digital Publishing Institute; 2016 [cited 2016 Oct 20];5:10 Available from: http://​www.​mdpi.​com/​2077-0383/​5/​1/​10
127.
Zurück zum Zitat Descamps B, Sewduth R, Ferreira Tojais N, Jaspard B, Reynaud A, Sohet F, et al. Frizzled 4 regulates arterial network organization through noncanonical WNT/planar cell polarity signaling. Circ Res [Internet]. 2012 [cited 2016 mar 22];110:47–58. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22076635. Descamps B, Sewduth R, Ferreira Tojais N, Jaspard B, Reynaud A, Sohet F, et al. Frizzled 4 regulates arterial network organization through noncanonical WNT/planar cell polarity signaling. Circ Res [Internet]. 2012 [cited 2016 mar 22];110:47–58. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​22076635.
133.
Zurück zum Zitat Ke H, Masoumi KC, Ahlqvist K, Seckl MJ, Rydell-Törmänen K, Massoumi R. Nemo-like kinase regulates the expression of vascular endothelial growth factor (VEGF) in alveolar epithelial cells. Sci Rep. [Internet]. 2016 [cited 2016 Jun 14];6:23987. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27035511. Ke H, Masoumi KC, Ahlqvist K, Seckl MJ, Rydell-Törmänen K, Massoumi R. Nemo-like kinase regulates the expression of vascular endothelial growth factor (VEGF) in alveolar epithelial cells. Sci Rep. [Internet]. 2016 [cited 2016 Jun 14];6:23987. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27035511.
141.
Zurück zum Zitat Ceteci F, Ceteci S, Karreman C, Kramer BW, Asan E, Götz R, et al. Disruption of tumor cell adhesion promotes angiogenic switch and progression to micrometastasis in RAF-driven murine lung cancer. Cancer Cell [Internet]. 2007 [cited 2016 mar 22];12:145–159. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17692806. Ceteci F, Ceteci S, Karreman C, Kramer BW, Asan E, Götz R, et al. Disruption of tumor cell adhesion promotes angiogenic switch and progression to micrometastasis in RAF-driven murine lung cancer. Cancer Cell [Internet]. 2007 [cited 2016 mar 22];12:145–159. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​17692806.
142.
Zurück zum Zitat Zhang X-X, Zhang L-L, Yang H-L, Wang X-W. Mechanism of WNT/β-catenin signaling pathway in enhanced malignant phenotype of non-small cell lung cancer induced by anti-angiogenesis therapy. Asian Pac J Trop Med. [Internet]. 2016 [cited 2016 mar 22];9:58–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26851788. Zhang X-X, Zhang L-L, Yang H-L, Wang X-W. Mechanism of WNT/β-catenin signaling pathway in enhanced malignant phenotype of non-small cell lung cancer induced by anti-angiogenesis therapy. Asian Pac J Trop Med. [Internet]. 2016 [cited 2016 mar 22];9:58–62. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​26851788.
150.
Zurück zum Zitat Fanjul-Fernandez M, Folgueras AR, Fueyo A, Balbin M, Suarez MF, Fernandez-Garcia MS, et al. Matrix Metalloproteinase Mmp-1a Is Dispensable for Normal Growth and Fertility in Mice and Promotes Lung Cancer Progression by Modulating Inflammatory Responses. J Biol Chem. [Internet]. 2013 [cited 2016 Jun 14];288:14647–14656 Available from: http://www.jbc.org/cgi/doi/10.1074/jbc.M112.439893 Fanjul-Fernandez M, Folgueras AR, Fueyo A, Balbin M, Suarez MF, Fernandez-Garcia MS, et al. Matrix Metalloproteinase Mmp-1a Is Dispensable for Normal Growth and Fertility in Mice and Promotes Lung Cancer Progression by Modulating Inflammatory Responses. J Biol Chem. [Internet]. 2013 [cited 2016 Jun 14];288:14647–14656 Available from: http://​www.​jbc.​org/​cgi/​doi/​10.​1074/​jbc.​M112.​439893
151.
Zurück zum Zitat Reynolds PR, Kasteler SD, Cosio MG, Sturrock A, Huecksteadt T, Hoidal JR. RAGE: developmental expression and positive feedback regulation by Egr-1 during cigarette smoke exposure in pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol. [Internet]. 2008 [cited 2016 Jun 14];294:L1094–L1101. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18390831. Reynolds PR, Kasteler SD, Cosio MG, Sturrock A, Huecksteadt T, Hoidal JR. RAGE: developmental expression and positive feedback regulation by Egr-1 during cigarette smoke exposure in pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol. [Internet]. 2008 [cited 2016 Jun 14];294:L1094–L1101. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​18390831.
152.
153.
Zurück zum Zitat Bartling B, Hofmann H-S, Weigle B, Silber R-E, Simm A. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis [Internet]. 2005 [cited 2016 Jun 14];26:293–301. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15539404. Bartling B, Hofmann H-S, Weigle B, Silber R-E, Simm A. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis [Internet]. 2005 [cited 2016 Jun 14];26:293–301. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15539404.
154.
155.
156.
Zurück zum Zitat Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol [Internet]. 2004 [cited 2015 Aug 14];22:2184–2191. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15169807. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol [Internet]. 2004 [cited 2015 Aug 14];22:2184–2191. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15169807.
157.
Zurück zum Zitat Van der Veldt AAM, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HNJM, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell [Internet]. Elsevier; 2012 [cited 2016 Mar 7];21:82–91 Available from: http://www.cell.com/article/S1535610811004466/fulltext Van der Veldt AAM, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HNJM, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell [Internet]. Elsevier; 2012 [cited 2016 Mar 7];21:82–91 Available from: http://​www.​cell.​com/​article/​S153561081100446​6/​fulltext
167.
Zurück zum Zitat Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. [Internet]. 2001 [cited 2016 Jun 14];7:1028–1034. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11533706. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. [Internet]. 2001 [cited 2016 Jun 14];7:1028–1034. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​11533706.
170.
Zurück zum Zitat Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, Kohnke H, et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J. [Internet]. 2011 [cited 2016 Jun 14];11:61–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20177420. Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, Kohnke H, et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J. [Internet]. 2011 [cited 2016 Jun 14];11:61–71. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​20177420.
171.
Zurück zum Zitat Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer [Internet]. 2009 [cited 2016 Jun 14];64:98–104. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18823676. Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer [Internet]. 2009 [cited 2016 Jun 14];64:98–104. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​18823676.
172.
Zurück zum Zitat Kim YH, Ishii G, Goto K, Ota S, Kubota K, Murata Y, et al. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer [Internet]. 2009 [cited 2016 Jun 14];65:105–111. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19036469. Kim YH, Ishii G, Goto K, Ota S, Kubota K, Murata Y, et al. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer [Internet]. 2009 [cited 2016 Jun 14];65:105–111. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​19036469.
173.
175.
Zurück zum Zitat Agrawal M, Abraham J, Balis FM, Edgerly M, Stein WD, Bates S, et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res. [Internet]. 2003 [cited 2016 Jun 14];9:650–656. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12576431. Agrawal M, Abraham J, Balis FM, Edgerly M, Stein WD, Bates S, et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res. [Internet]. 2003 [cited 2016 Jun 14];9:650–656. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​12576431.
176.
Zurück zum Zitat Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res. [Internet]. 2011 [cited 2016 Jun 14];17:569–580. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21081657. Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res. [Internet]. 2011 [cited 2016 Jun 14];17:569–580. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​21081657.
177.
Zurück zum Zitat Kelly RJ, Robey RW, Chen CC, Draper D, Luchenko V, Barnett D, et al. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors. Oncologist [Internet]. 2012 [cited 2016 Jun 14];17:512. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22416063. Kelly RJ, Robey RW, Chen CC, Draper D, Luchenko V, Barnett D, et al. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors. Oncologist [Internet]. 2012 [cited 2016 Jun 14];17:512. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​22416063.
186.
Zurück zum Zitat Li X-Q, Yang X-L, Zhang G, Wu S-P, Deng X-B, Xiao S-J, et al. Nuclear β-catenin accumulation is associated with increased expression of Nanog protein and predicts poor prognosis of non-small cell lung cancer. J Transl Med [Internet]. 2013 [cited 2017 may 12];11:114. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23648139. Li X-Q, Yang X-L, Zhang G, Wu S-P, Deng X-B, Xiao S-J, et al. Nuclear β-catenin accumulation is associated with increased expression of Nanog protein and predicts poor prognosis of non-small cell lung cancer. J Transl Med [Internet]. 2013 [cited 2017 may 12];11:114. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23648139.
189.
Zurück zum Zitat Wei Q, Zhao Y, Yang Z-Q, Dong Q-Z, Dong X-J, Han Y, et al. Dishevelled family proteins are expressed in non-small cell lung cancer and function differentially on tumor progression. Lung Cancer [Internet]. 2008 [cited 2017 may 12];62:181–192. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18692936. Wei Q, Zhao Y, Yang Z-Q, Dong Q-Z, Dong X-J, Han Y, et al. Dishevelled family proteins are expressed in non-small cell lung cancer and function differentially on tumor progression. Lung Cancer [Internet]. 2008 [cited 2017 may 12];62:181–192. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​18692936.
193.
Zurück zum Zitat Fukui T, Kondo M, Ito G, Maeda O, Sato N, Yoshioka H, et al. Transcriptional silencing of secreted frizzled related protein 1 (SFRP1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene [Internet]. 2005 [cited 2017 may 12];24:6323–6327. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16007200. Fukui T, Kondo M, Ito G, Maeda O, Sato N, Yoshioka H, et al. Transcriptional silencing of secreted frizzled related protein 1 (SFRP1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene [Internet]. 2005 [cited 2017 may 12];24:6323–6327. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​16007200.
203.
Zurück zum Zitat Tan M, Wu J, Cai Y. Suppression of WNT signaling by the miR-29 family is mediated by demethylation of WIF-1 in non-small-cell lung cancer. Commun: Biochem. Biophys. Res; 2013. Tan M, Wu J, Cai Y. Suppression of WNT signaling by the miR-29 family is mediated by demethylation of WIF-1 in non-small-cell lung cancer. Commun: Biochem. Biophys. Res; 2013.
204.
Zurück zum Zitat Xu W, Ji J, Xu Y, Liu Y, Shi L, Liu Y, et al. MicroRNA-191, by promoting the EMT and increasing CSC-like properties, is involved in neoplastic and metastatic properties of transformed human bronchial epithelial cells. Mol Carcinog. [Internet]. 2015 [cited 2016 Nov 22];54:E148–E161 Available from: http://doi.wiley.com/10.1002/mc.22221 Xu W, Ji J, Xu Y, Liu Y, Shi L, Liu Y, et al. MicroRNA-191, by promoting the EMT and increasing CSC-like properties, is involved in neoplastic and metastatic properties of transformed human bronchial epithelial cells. Mol Carcinog. [Internet]. 2015 [cited 2016 Nov 22];54:E148–E161 Available from: http://​doi.​wiley.​com/​10.​1002/​mc.​22221
205.
207.
Zurück zum Zitat Zhou R, Zhou X, Yin Z, Guo J, Hu T, Jiang S, et al. MicroRNA-574-5p promotes metastasis of non-small cell lung cancer by targeting PTPRU. Sci Rep. [Internet]. Nature Publishing Group; 2016 [cited 2016 Nov 22];6:35714 Available from: http://www.nature.com/articles/srep35714 Zhou R, Zhou X, Yin Z, Guo J, Hu T, Jiang S, et al. MicroRNA-574-5p promotes metastasis of non-small cell lung cancer by targeting PTPRU. Sci Rep. [Internet]. Nature Publishing Group; 2016 [cited 2016 Nov 22];6:35714 Available from: http://​www.​nature.​com/​articles/​srep35714
208.
Zurück zum Zitat Jang JS, Jeon H-S, Sun Z, Aubry MC, Tang H, Park C-H, et al. Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res. [Internet]. NIH Public Access; 2012 [cited 2016 Nov 22];18:3658–3667. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22573352. Jang JS, Jeon H-S, Sun Z, Aubry MC, Tang H, Park C-H, et al. Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res. [Internet]. NIH Public Access; 2012 [cited 2016 Nov 22];18:3658–3667. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​22573352.
Metadaten
Titel
WNT signaling – lung cancer is no exception
verfasst von
Judit Rapp
Luca Jaromi
Krisztian Kvell
Gyorgy Miskei
Judit E. Pongracz
Publikationsdatum
01.12.2017
Verlag
BioMed Central
Erschienen in
Respiratory Research / Ausgabe 1/2017
Elektronische ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-017-0650-6

Weitere Artikel der Ausgabe 1/2017

Respiratory Research 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.